A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)

Phase 1

Recruiting

• Conditions: ovel Coronavirus Pneumonia (COVID-19)

• Registration Number: ITMCTR2000003077
• Lead Sponsor: Shanghai University of TCM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;
2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)
3. aged 18 to 65 years;
4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.

Exclusion Criteria

1. Patients with mild and critical novel coronavirus pneumonia;
2. Acute respiratory disease caused by non- novel coronavirus pneumonia;
3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;
4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;
5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies;
6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;
7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;
8. Researchers find the patient inappropriate to be involved in the trial.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effective rate of TCM symptoms;fever clearance time;

Secondary Outcome Measures

Name	Time	Method
lung CT scan;TCM sympton score;Oxygen saturation;blood routine test;duration of hospital stay;severe and critical conversion rates;clearance time of COVID-19;body tempture;